Marizyme OTC Stock Executives
MRZM Stock | USD 0.04 0.01 20.00% |
Marizyme employs about 11 people. The company is managed by 8 executives with a total tenure of roughly 26 years, averaging almost 3.0 years of service per executive, having 1.38 employees per reported executive. Analysis of Marizyme's management performance can provide insight into the firm performance.
Kari Jacobson Insider Controller |
Stefan Strobel Insider Head Europe |
Marizyme |
Marizyme Management Team Effectiveness
The company has return on total asset (ROA) of (0.1468) % which means that it has lost $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4956) %, meaning that it created substantial loss on money invested by shareholders. Marizyme's management efficiency ratios could be used to measure how well Marizyme manages its routine affairs as well as how well it operates its assets and liabilities.Marizyme Workforce Comparison
Marizyme is considered to be number one stock in number of employees category among its peers. The total workforce of Information Technology industry is now estimated at about 351. Marizyme holds roughly 11.0 in number of employees claiming about 3% of equities under Information Technology industry.
Marizyme Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Marizyme Price Series Summation is a cross summation of Marizyme price series and its benchmark/peer.
Marizyme Notable Stakeholders
A Marizyme stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Marizyme often face trade-offs trying to please all of them. Marizyme's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Marizyme's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Kari Jacobson | Controller | Profile | |
Stefan Strobel | Head Europe | Profile | |
George CPA | CFO Treasurer | Profile | |
Claudio MD | Chief Logic | Profile | |
Harrison CFA | VP Fin | Profile | |
David MBA | S CEO | Profile | |
FACC MBA | Ex Officer | Profile | |
Catherine Pachuk | Ex Officer | Profile |
About Marizyme Management Performance
The success or failure of an entity such as Marizyme often depends on how effective the management is. Marizyme management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Marizyme management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Marizyme management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business. Marizyme, Inc. was incorporated in 2007 and is based in Jupiter, Florida. Marizyme operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 11 people.
The data published in Marizyme's official financial statements typically reflect Marizyme's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Marizyme's quantitative information. For example, before you start analyzing numbers published by Marizyme accountants, it's essential to understand Marizyme's liquidity, profitability, and earnings quality within the context of the Software space in which it operates.
Marizyme Workforce Analysis
Traditionally, organizations such as Marizyme use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Marizyme within its industry.Marizyme Manpower Efficiency
Return on Marizyme Manpower
Revenue Per Employee | 19.1K | |
Revenue Per Executive | 26.3K | |
Net Loss Per Employee | 999.8K | |
Net Loss Per Executive | 1.4M |
Other Information on Investing in Marizyme OTC Stock
Marizyme financial ratios help investors to determine whether Marizyme OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Marizyme with respect to the benefits of owning Marizyme security.